155 related articles for article (PubMed ID: 32063809)
1. Ceftolozane/Tazobactam Dosing Requirements Against
Ruiz J; Ferrada A; Salavert M; Gordon M; Villarreal E; Castellanos-Ortega Á; Ramirez P
Dose Response; 2020; 18(1):1559325819885790. PubMed ID: 32063809
[TBL] [Abstract][Full Text] [Related]
2. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
[TBL] [Abstract][Full Text] [Related]
6. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R
Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
[TBL] [Abstract][Full Text] [Related]
9. Cefepime Dosing Requirements in Elderly Patients Attended in the Emergency Rooms.
Ruiz-Ramos J; Herrera-Mateo S; López-Vinardell L; Juanes-Borrego A; Puig-Campmany M; Mangues-Bafalluy MA
Dose Response; 2022; 20(1):15593258221078393. PubMed ID: 35237115
[TBL] [Abstract][Full Text] [Related]
10. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and
Gerlach AT; Wenzler E; Hunt LN; Bazan JA; Bauer KA
Int J Crit Illn Inj Sci; 2019; 9(3):138-143. PubMed ID: 31620353
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.
Bremmer DN; Nicolau DP; Burcham P; Chunduri A; Shidham G; Bauer KA
Pharmacotherapy; 2016 May; 36(5):e30-e33. PubMed ID: 27012450
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
15. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Craig WA; Andes DR
Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659
[TBL] [Abstract][Full Text] [Related]
16. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Noel AR; Bowker KE; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
[TBL] [Abstract][Full Text] [Related]
20. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]